Latest Progressive familial intrahepatic cholestasis Stories
GOTHENBURG, Sweden, February 5, 2015 /PRNewswire/ -- Albireo today announced initiation of a phase II trial with A4250, the company's lead compound for cholestatic liver
CAMEO Phase 2 Clinical Trial of LUM001 Now Enrolling Adults with Primary Sclerosing Cholangitis SAN DIEGO, May 9, 2014 /PRNewswire/ --
Funding to support clinical development of treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis SAN DIEGO, March 11, 2014 /PRNewswire/ -- Lumena Pharmaceuticals
- Large; stout; burly.